The Ruling of Novel Drugs to the Molecular Targets on Variant Pathological

DOI

10.2991/978-2-38476-273-6_2How to use a DOI?

Keywords

Bioinformatic tools; Pharmacogenomic; Repurposing drug

Abstract

In recent decades, the investigation of novel drugs have not only been fully characterized at the molecular level, but have also been used in significant pharmacogenomic research. Our paper presents the ruling of novel drugs to molecular targets on variant pathological. Furthermore, in this study, we show the map of bioinformatics field work, notably clinicaltrials.gov which is integrated with feeder applications. The study involves literature indexed by Scopus, and PubMed databases, and the search uses a combination of the following keyword variants; “ClinicalTrials.gov AND Genomic”, “ClinicalTrials.gov AND repurposing drug”. This study used original articles in English which has published during 2022. Thus, the screening results of library sources were narrowed to four original papers that met the inclusion criteria. We map that a total of nine tools have been integrated with each other for the goals of gene analysis and repurposing medication selection, based on a published approach that incorporates bioinformatics tools, which include: Gwas Catalog, National Biobank Consortioum of Taiwan, Cancer Cell Line of Ensiklopedia, HaploReg, STRING, Drugbank, ClinicalTrials.gov, Pubmed.gov, and ConectivityMap. Our review results the present 12 lists of repurposing drugs, two of which (geldanamycin and fulvestrant) have the potential to be developed as breast cancer treatments, two new antidepressant drugs (Sarilumab and Satralizumab), seven new colorectal cancer drugs (sulindac, celecoxib, naproxen rucaparib, ibuprofen, balsalazide, aspirin), and one new drug highly recommended (Belatacept).

Copyright

© 2024 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Henik Setiyaningsih
AU  - Imron Wahyu Hidayat
AU  - Alfian Syarifuddin
AU  - Setiyo Budi Santoso
AU  - Ratna Wijayatri
PY  - 2024
DA  - 2024/08/02
TI  - The Ruling of Novel Drugs to the Molecular Targets on Variant Pathological
BT  - Proceedings of 5th Borobudur International Symposium on Humanities and Social Science 2023
PB  - Atlantis Press
SP  - 4
EP  - 13
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-38476-273-6_2
DO  - 10.2991/978-2-38476-273-6_2
ID  - Setiyaningsih2024
ER  -